BI 655130 (spesolimab)

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Healthy

Phase 1

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

CompletedNCT02525679

Boehringer IngelheimHealthy

Start: 2015-09-14End: 2016-05-27Updated: 2024-03-15

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

CompletedNCT02852824

Boehringer IngelheimHealthy

Start: 2016-08-10End: 2017-08-01Updated: 2024-03-18

Related Papers

Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies

Clinical Pharmacokinetics2022-12-0110 citations